NCT03930641View on ClinicalTrials.gov

Study of the Safety of Brolucizumab 6 mg in Prefilled Syringe in Patients With Neovascular Age Related Macular Degeneration

PHASE3CompletedINTERVENTIONAL
Enrollment

34

Participants

Timeline

Start Date

May 23, 2019

Primary Completion Date

July 2, 2019

Study Completion Date

July 2, 2019

Conditions
Neovascular Age Related Macular Degeneration
Interventions
DRUG

RTH258

6 mg in prefilled syringe

Trial Locations (3)

23235

Novartis Investigative Site, Richmond

32503

Novartis Investigative Site, Pensacola

32701

Novartis Investigative Site, Altamonte Springs

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY